HUMA — Humacyte, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1818382 ·
Last close
$0.65
Market Cap
$176.18M
52W High
$1.52
52W Low
$0.61
ADV30
12,908,938
Next earnings
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 495,000 -1,543,000 -28,935,000 -17,619,000 110,557,000 48,539,000 98,933,000
Dec 2025 467,000 -8,615,000 -30,836,000 -24,804,000 116,366,000 50,497,000 113,257,000
Sep 2025 753,000 493,000 -24,390,000 -17,510,000 91,509,000 19,488,000 96,260,000
Jun 2025 301,000 88,000 -29,727,000 -37,658,000 138,795,000 38,032,000 134,743,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-101,545,000
Investing CF
$-831,000
Financing CF
$38,068,000
CapEx
$-831,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-0.16
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-744,467,000
Inventory
$9,920,000
Receivables
$434,000
ST Investments
EBIT TTM
$-87,070,000
Pretax Income TTM
$-97,591,000
Interest Exp TTM
$10,521,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,016,000
EBITDA
$-105,185,000
Free Cash Flow
$-64,806,624
Enterprise Value
$167,070,032
Total Cash
$48,539,000
Total Debt
$66,501,000
Shares Out
269,638,156
Trailing EPS
$-0.63
Book Value
$0.05
ROE
-409.5%
ROA
-51.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,038,000 -108,137,000 -40,833,000 116,366,000 113,257,000 -105,042,000
Dec 2024 0 -114,398,000 -148,701,000 137,872,000 190,541,000 -98,122,000
Dec 2023 0 -100,047,000 -110,776,000 128,223,000 114,677,000 -73,305,000
Dec 2022 0 -84,578,000 -11,965,000 204,302,000 87,374,000 -71,129,000

TTM Snapshot

Revenues TTM
$2,255,000
NetIncome TTM
$-122,041,000
OpCashFlow TTM
$0
Assets (Latest)
$137,872,000
Forward EPS
$-0.24

Peers — same industry

TickerNameMarket CapLastDaily %
ACOG Alpha Cognition Inc. $180.29M $8.28
DTIL PRECISION BIOSCIENCES INC $180.36M $6.99
OTLK Outlook Therapeutics, Inc. $182.62M $0.98
VYGR Voyager Therapeutics, Inc. $183.08M $3.03
ALEC Alector, Inc. $167.65M $1.51

News headlines (Yahoo Finance, 1h cache)

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
2026-07-28 22:00 · Yahoo
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
2026-07-27 12:00 · Yahoo
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
2026-07-21 22:00 · Yahoo
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
2026-07-20 22:15 · Yahoo
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
2026-07-14 12:00 · Yahoo
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
2026-06-30 22:00 · Yahoo
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data
2026-06-27 14:06 · Yahoo
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
2026-06-25 22:15 · Yahoo
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
2026-06-19 13:30 · Yahoo
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
2026-06-16 22:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.